Losartan

Status
Phase 2
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Losartan is an angiotensin II receptor antagonists. It keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. 

Study Details

There are multiple studies involving losartan and its effect on COVID-19 prevention or progression. Click the icon below to learn about the various studies.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >